用户名:  密码:   
网站首页即时通讯活动公告最新消息科技前沿学人动向两岸三地人在海外历届活动关于我们联系我们申请加入
栏目导航 — 美国华裔教授专家网科技动向生物医学
关键字  范围   
 
FDA:Recently Approved Devices
FDA:Recently Approved Devices
9/4/2019 1:01:26 AM | 浏览:128 | 评论:0

FDA:Recently Approved Devices

 

Recently Approved Devices

 

The FDA recently approved the following devices to be marketed.

 

FDA:Recently Approved Devices

 

Minimally Invasive Deformity Correction(MID-C)System - H170001

The Minimally Invasive Deformity Correction(MID-C)System is a non-fusion spinal device intended to prevent spinal curve progression in adolescent patients with idiopathic scoliosis. The MID-C System includes a ratcheting rod made from titanium alloy components that is attached to the spine using screws.

 

FDA:Recently Approved Devices

 

BAROSTIM NEO System - P180050

The BAROSTIM NEO System includes an implantable pulse generator(IPG), a carotid sinus lead kit and a programmer. The IPG delivers electrical signals to the body's pressure sensors(baroreceptors)in patients with advanced heart failure.

 

The programmer allows medical personnel to control the settings of the device.

 

FDA:Recently Approved Devices

The Tether™ - Vertebral Body Tethering System - H190005

The Tether™ - Vertebral Body Tethering System is a non-fusion spinal device intended to treat idiopathic scoliosis, an abnormal curvature in the spine that occurs without a known cause, in young patients whose bones have not fully matured. The Tether™ - Vertebral Body Tethering System is made up of:anchors, bone screws, cord, and set screws. The anchors, bone screws and set screws are made out of titanium alloys that are commonly used as spine implants. The cord is made of a strong flexible polymer, SULENE® PET(polyethylene-terephthalate).

 

 

FDA:Recently Approved Devices

 

Medtronic CoreValve Evolut R System and Medtronic CoreValve Evolut PRO System - P130021/S058

The Medtronic CoreValve Evolut R System and Medtronic CoreValve Evolut PRO System each consists of a transcatheter aortic valve(TAV), a delivery catheter, and a loading system. The TAV is an artificial heart valve made of pig tissue attached to a flexible, self-expanding nickel-titanium(Nitinol)frame for support.

 

This approval expands the indications for use for both to patients at low risk for surgical therapy.

 

 

FDA:Recently Approved Devices

 

Edwards SAPIEN 3 Transcatheter Heart Valve System and Edwards SAPIEN 3 Ultra Transcatheter Heart Valve System - P140031/S085

The Edwards SAPIEN 3 Transcatheter Heart Valve(THV)System and Edwards SAPIEN 3 Ultra THV System each consists of a catheter-based artificial aortic heart valve and accessories used to implant the valve without open-heart surgery. The valve is made of cow tissue attached to a balloon-expandable, cobalt-chromium frame for support.

 

This approval expands the indications for use for both to patients at low risk for surgical therapy.

 

 

FDA:Recently Approved Devices

 

PD-L1 IHC 22C3 pharmDx - P150013/S016

The PD-L1 IHC 22C3 pharmDx is a laboratory test doctors can use to identify the protein programmed cell death ligand 1(PD-L1)in tumor tissue obtained from patients who have esophageal squamous cell cancer.

 

This lab test was previously approved to identify the PL-L1 tumor in patients with lung, gastric, urothelial, cervical and head and neck cancer.  This approval expands the indications for use for this test for determining whether patients with esophageal squamous cell cancer are eligible for treatment with the medicine KEYTRUDA®(pembrolizumab).

 

 

 

FDA:Recently Approved Devices

MED-EL Cochlear Implant System - P000025/S104

The MED-EL Cochlear Implant System is intended to produce auditory sensations by providing electric stimulation in the cochlea.

 

This approval expands the current cochlear implantation indications to include patients 5 years and older with single sided deafness(SSD)and asymmetric hearing loss(AHL)who have profound sensorineural hearing loss in the ear to be implanted and normal hearing or mild to moderate sensorineural hearing loss in the other ear.

 

 

FDA:Recently Approved Devices

 

Medtronic CoreValve System; Medtronic CoreValve Evolut R System; Medtronic CoreValve Evolut PRO System - P130021/S033

The Medtronic CoreValve family of devices is comprised of three design iterations:the Medtronic CoreValve System(1st generation), the Medtronic CoreValve Evolut R System(2nd generation); Medtronic CoreValve Evolut PRO System(3rd generation). Each system consists of a transcatheter aortic valve(TAV), a delivery catheter, and a loading system. The TAV is an artificial heart valve made of pig tissue attached to a flexible, self-expanding nickel-titanium(Nitinol)frame for support.

 

This approval expands the indications for use to patients at intermediate risk for surgical therapy.

 

 

FDA:Recently Approved Devices

 

PD-L1 IHC 22C3 pharmDx - P150013/S014

The PD-L1 IHC 22C3 pharmDx  is a lab test doctors use to see if patients who have head and neck squamous cell cancer have programmed cell death ligand 1(PD-L1)in their cancer.

 

This lab test was previously approved to identify the PD-L1 tumor in patients with lung, gastric, cervical and urothelial cancer for treatment with KEYTRUDA®. This approval expands the indications for use for this test for determining whether patients with head or neck squamous cell cancer are eligible for treatment with the medicine KEYTRUDA®(pembrolizumab).

 

 

FDA:Recently Approved Devices

 

HeartStart OnSite Defibrillator(Model M5066A), HeartStart Home Defibrillator(Model M5068A), Primary Battery(Model M5070A), SMART Pads Cartridges(Adult Model M5071A)and Infant/Child(Model M5072A)- P160029

The HeartStart OnSite(M5066A)and HeartStart Home(M5068A)are automatic external defibrillators(AED)designed to treat people experiencing sudden cardiac arrest(SCA), a medical condition in which the heart suddenly and unexpectedly stops beating.

 

 

FDA:Recently Approved Devices

 

Eversense Continuous Glucose Monitoring System - P160048/S006

The Eversense Continuous Glucose Monitoring System is a prescription device that provides real-time glucose monitoring every five minutes for up to 90 days at a time for people with diabetes. The system consists of an implantable fluorescence-based sensor, a smart transmitter, and a mobile app for displaying glucose values, trends and alerts on the patient's compatible mobile device(smart phone, tablet, etc.).

 

This supplement expands the indications for the Eversense CGM system to allow for replacement of fingerstick blood glucose testing for diabetes treatment decisions.

 

 

FDA:Recently Approved Devices

 

Hintermann Series H3™ Total Ankle Replacement System - P160036

The Hintermann Series H3™ Total Ankle Replacement System is an implanted medical device intended to replace a painful arthritic ankle joint in the first surgical treatment for the joint(primary surgery).

 

 

FDA:Recently Approved Devices

 

TransMedics OCS Lung System - P160013/S002

The TransMedics OCS Lung System is designed to preserve donor lungs prior to transplantation. The TransMedics OCS Lung System includes a portable enclosure with mechanical and electrical components used to warm, ventilate and perfuse the lungs(i.e., supply with fluid), as well as a lung preservation solution combined with packed red blood cells. Prior to transplantation, the device enables the transplant team to monitor and assess the donor lungs while they are being perfused.

 

This approval expands the indications for use to include preservation of donor lung pairs initially deemed unacceptable for transplantation based on limitations of cold storage preservation.

 

 

FDA:Recently Approved Devices

 

therascreen PIK3CA RGQ PCR Kit - P190001 and P190004

The therascreen® PIK3CA RGQ PCR Kit is a laboratory test doctors use to detect 11 mutations in the PIK3CA gene in tumor tissue or in the colorless fluid part of blood(plasma)from patients with advanced or metastatic breast cancer.  In breast cancer tissue, mutations in the PIK3CA gene causes an altered form of the PIK3CA protein and result in abnormal functioning of the protein. Identifying these mutations will help patients with breast cancer get a personalized treatment that target these genetic changes.

 

FDA:Recently Approved Devices

 

U.S. Food and Drug Administration
10903 New Hampshire Avenue, Silver Spring, MD 20993
1-888-INFO-FDA(1-888-463-6332)
Privacy Policy | www.fda.gov
Manage Preferences or Unsubscribe from this List | Unsubscribe from all Email Lists

 

FDA:Recently Approved Devices

 

相关栏目:『生物医学
英国惠康桑格研究所:人体内的微生物与出生方式有关 2019-09-19 [39]
老年人喝水,这几点要格外注意 2019-09-18 [84]
BBC:素食与纯素食者中风风险或许更高 2019-09-18 [54]
牛津大学科学家首次识别出与左撇子相关的基因区域 2019-09-17 [36]
加州理工学院研究发现:信息编码神经元越多 形成记忆越持久 2019-09-11 [122]
医药发展近期动向 2019-09-11 [152]
牛津大学AI技术可提前5年预测心脏病发作风险 2019-09-05 [227]
借助光声断层成像技术让纳米机器人实现药物递送,或进行智能微手术 2019-09-04 [132]
全球近期肠道菌群研究动向 2019-09-04 [321]
英国爱丁堡大学:体细胞突变,会加速衰老进程增加疾病风险 2019-09-03 [121]
相关栏目更多文章
最新图文:
:中国336个国家重点实验室布局 :中澳政府联合出手打击洗钱和逃税漏税 大量中国居民海外账户遭冻结 :摄影师苏唐诗与寂寞百年的故宫对话6年,3万张照片美伦美奂 :大数据分析图解:2019中国企业500强 张梦然:英国惠康桑格研究所:人体内的微生物与出生方式有关 :美众议院将调查华裔部长赵小兰“利用职权为家族谋利“ :UCLA CCS 2019 Fall Quarter Lecture Series Overview :美国参众两院新排华法案强行闯关失败,全体华人须警惕法案卷土重来
更多最新图文
更多《即时通讯》>>
 
打印本文章
 
您的名字:
电子邮件:
留言内容:
注意: 留言内容不要超过4000字,否则会被截断。
未 审 核:  是
  
关于我们联系我们申请加入后台管理设为主页加入收藏
美国华裔教授专家网版权所有,谢绝拷贝。如欲选登或发表,请与美国华裔教授专家网联系。
Copyright © 2019 ScholarsUpdate.com. All Rights Reserved.